$207B Market Shift: The Race for Fast Track Approval in Oncology [Globe and Mail, The (Toronto, Canada)]
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium [Globe and Mail, The (Toronto, Canada)]
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors [Globe and Mail, The (Toronto, Canada)]